About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 673132, 7 pages
http://dx.doi.org/10.1155/2012/673132
Research Article

Effects of Berberine and Hwangryunhaedok-Tang on Oral Bioavailability and Pharmacokinetics of Ciprofloxacin in Rats

1KM-Based Herbal Drug Research Group, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea
2Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University, Republic of Korea

Received 31 July 2012; Revised 25 September 2012; Accepted 26 September 2012

Academic Editor: Bhushan Patwardhan

Copyright © 2012 Youn-Hwan Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Lu, J. Song, F. Huang et al., “Comparative pharmacokinetics of baicalin after oral administration of pure baicalin, Radix scutellariae extract and Huang-Lian-Jie-Du-Tang to rats,” Journal of Ethnopharmacology, vol. 110, no. 3, pp. 412–418, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. S. Hwang, C. Y. Shin, Y. Huh, and J. H. Ryu, “Hwangryun-Hae-Dok-tang (Huanglian-Jie-Du-Tang) extract and its constituents reduce ischemia-reperfusion brain injury and neutrophil infiltration in rats,” Life Sciences, vol. 71, no. 18, pp. 2105–2117, 2002. View at Scopus
  3. A. Singh, S. Duggal, N. Kaur, et al., “Berberine: alkaloid with wide spectrum of pharmacological activities,” Journal of Natural Products, vol. 3, pp. 64–75, 2010.
  4. H. Xu, T. Zhang, X. Zhu, et al., “Recent advance on chemical compositions and pharmacodynamic and pharmacokinetic studies of Rhizoma Coptidis,” Asian Journal of Pharmacodynamics and Pharmacokinetics, vol. 9, no. 1, pp. 11–25, 2009.
  5. N. K. Dutta, P. H. Marker, and N. R. Rao, “Berberine in toxin-induced experimental cholera,” British Journal of Pharmacology, vol. 44, no. 1, pp. 153–159, 1972. View at Scopus
  6. K. A. Head, “Natural approaches to prevention and treatment of infections of the lower urinary tract,” Alternative Medicine Review, vol. 13, no. 3, pp. 227–244, 2008. View at Scopus
  7. H. S. Abou-Auda, A. A. Mustafa, and M. S. Al-Humayyd, “Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin,” Biopharmaceutics and Drug Disposition, vol. 29, no. 1, pp. 29–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Stavri, L. J. V. Piddock, and S. Gibbons, “Bacterial efflux pump inhibitors from natural sources,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 6, pp. 1247–1260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Jayaraman, M. K. Sakharkar, C. S. Lim, T. H. Tang, and K. R. Sakharkar, “Activity and interactions of antibiotic and phytochemical combinations against pseudomonas aeruginosa in vitro,” International Journal of Biological Sciences, vol. 6, no. 6, pp. 556–568, 2010. View at Scopus
  10. C. Seral, S. Carryn, P. M. Tulkens, and F. Van Bambeke, “Influence of P-glycoprotein and MRP effux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 5, pp. 1167–1173, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Qiu, X. H. Jiang, C. X. Liu, Y. Ju, and J. X. Jin, “Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp,” Phytotherapy Research, vol. 23, no. 11, pp. 1553–1558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Zhang, F. Qiu, J. Jiang, C. Gao, and Y. Tan, “Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein,” Xenobiotica, vol. 41, no. 4, pp. 290–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. J. Yang, J. B. Weon, and J. Y. Ma, “Simultaneous analysis of three maker components in Hwangryunhaedok-tang by HPLC-DAD,” Yakhak Hoeji, vol. 55, no. 1, pp. 64–68, 2011.
  14. Y. H. Hwang, T. Kim, W. K. Cho, et al., “Food- and gender-dependent pharmacokinetics of paeoniflorin after oral administration with Samul-tang in rats,” Journal of Ethnopharmacology, vol. 142, no. 1, pp. 161–167, 2012.
  15. Z. Hu, X. Yang, P. C. L. Ho et al., “Herb-drug interactions: a literature review,” Drugs, vol. 65, no. 9, pp. 1239–1282, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Cott, “Herb-drug interactions: focus on pharmacokinetics,” CNS Spectrums, vol. 6, no. 10, pp. 827–832, 2001. View at Scopus
  17. R. L. Nahin, J. M. Dahlhamer, and B. J. Stussman, “Health need and the use of alternative medicine among adults who do not use conventional medicine,” BMC Health Services Research, vol. 10, article 220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. P. R. Vuddanda, S. Chakraborty, and S. Singh, “Berberine: a potential phytochemical with multispectrum therapeutic activities,” Expert Opinion on Investigational Drugs, vol. 19, no. 10, pp. 1297–1307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Yin, H. Xing, and J. Ye, “Efficacy of berberine in patients with type 2 diabetes mellitus,” Metabolism, vol. 57, no. 5, pp. 712–717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. EMEA, “Guideline on bioanalytical method validation,” European Medicines Agency, Committee for Medicinal Products for Human Use EMEA/CHMP/EW/192217/2009, 2011.
  21. B. Nouaille-Degorce, C. Veau, S. Dautrey et al., “Influence of renal failure on ciprofloxacin pharmacokinetics in rats,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 2, pp. 289–292, 1998. View at Scopus
  22. P. Joyanes, A. Pascual, M. J. Giménez, I. García, L. Aguilar, and E. Perea, “Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae,” Chemotherapy, vol. 47, no. 6, pp. 409–414, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. C. E. Thorburn and D. I. Edwards, “The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance,” Journal of Antimicrobial Chemotherapy, vol. 48, no. 1, pp. 15–22, 2001. View at Scopus
  24. E. Szałek, A. Kamińska, J. Gozdzik-Spychalska, E. Grześkowiak, and H. Batura-Gabryel, “The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis,” Acta Poloniae Pharmaceutica, vol. 68, no. 5, pp. 777–783, 2011. View at Scopus
  25. M. E. Cavet, M. West, and N. L. Simmons, “Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells,” British Journal of Pharmacology, vol. 121, no. 8, pp. 1567–1578, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. M. S. Park, H. Okochi, and L. Z. Benet, “Is ciprofloxacin a substrate of P-glycoprotein?” Archives of Drug Information, vol. 4, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Dautrey, K. Felice, A. Petiet, B. Lacour, C. Carbon, and R. Farinotti, “Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates,” British Journal of Pharmacology, vol. 127, no. 7, pp. 1728–1734, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Žakelj, K. Šturm, and A. Kristl, “Ciprofloxacin permeability and its active secretion through rat small intestine in vitro,” International Journal of Pharmaceutics, vol. 313, no. 1-2, pp. 175–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Shitan, M. Tanaka, K. Terai, K. Ueda, and K. Yazaki, “Human MDR1 and MRP1 recognize berberine as their transport substrate,” Bioscience, Biotechnology and Biochemistry, vol. 71, no. 1, pp. 242–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Efferth, M. Davey, A. Olbrich, G. Rücker, E. Gebhart, and R. Davey, “Activity of drugs from traditional chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells,” Blood Cells, Molecules, and Diseases, vol. 28, no. 2, pp. 160–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Suzuki, H. Tanabe, H. Mizukami, and M. Inoue, “Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine,” Biological and Pharmaceutical Bulletin, vol. 33, no. 4, pp. 677–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. I. I. Severina, M. S. Muntyan, K. Lewis, and V. P. Skulachev, “Transfer of cationic antibacterial agents berberine, palmatine, and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane,” IUBMB Life, vol. 52, no. 6, pp. 321–324, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. F. R. Stermitz, P. Lorenz, J. N. Tawara, L. A. Zenewicz, and K. Lewis, “Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 4, pp. 1433–1437, 2000. View at Scopus
  34. H. L. Lin, T. Y. Liu, W. Y. Lui, et al., “Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells,” Cancer, vol. 85, no. 9, pp. 1937–1942, 1999.
  35. H. J. Maeng, H. J. Yoo, I. W. Kim, I. S. Song, S. J. Chung, and C. K. Shim, “P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers,” Journal of Pharmaceutical Sciences, vol. 91, no. 12, pp. 2614–2621, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. H. L. Lin, T. Y. Liu, C. W. Wu, and C. W. Chi, “Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel,” British Journal of Cancer, vol. 81, no. 3, pp. 416–422, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. J. P. Fillastre, A. Leroy, B. Moulin, M. Dhib, F. Borsa-Lebas, and G. Humbert, “Pharmacokinetics of quinolones in renal insufficiency,” Journal of Antimicrobial Chemotherapy, vol. 26, supplement B, pp. 51–60, 1990. View at Scopus
  38. Y. Guo, Y. Chen, Z.-R. Tan, C. D. Klaassen, and H.-H. Zhou, “Repeated administration of berberine inhibits cytochromes P450 in humans,” European Journal of Clinical Pharmacology, vol. 68, no. 2, pp. 213–217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Zuo, N. Nakamura, T. Akao, and M. Hattori, “Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry,” Drug Metabolism and Disposition, vol. 34, no. 12, pp. 2064–2072, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Yu, H. Zhang, F. PanJun, et al., “Determination and preliminary studies of metabolism of berberine in human urine after oral administration,” Chinese Journal of Clinical Pharmacology, vol. 16, pp. 36–39, 2000.
  41. P. L. Tsai and T. H. Tsai, “Hepatobiliary excretion of berberine,” Drug Metabolism and Disposition, vol. 32, no. 4, pp. 405–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. S. S. Xie, N. Hu, X. Y. Jing et al., “Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats,” Journal of Pharmacy and Pharmacology, vol. 62, no. 4, pp. 440–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Y. Lai, S. L. Hsiu, Y. C. Hou, S. Y. Tsai, and P. D. L. Chao, “Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis,” Planta Medica, vol. 70, no. 2, pp. 132–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Fan, W. Zhang, D. Guo et al., “The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1,” Clinical Pharmacology and Therapeutics, vol. 83, no. 3, pp. 471–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Li, M. Kim, H. Choi, and J. Choi, “Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein,” Archives of Pharmacal Research, vol. 34, no. 11, pp. 1965–1972, 2011. View at Publisher · View at Google Scholar · View at Scopus